Emerging antibody-based products

Current Topics in Microbiology and Immunology

Volumn 375, Issue , 2014, Pages 107-126

  Whaley, Kevin J ^a   Morton, Josh ^b   Hume, Steve ^b   Hiatt, Ernie ^b   Bratcher, Barry ^b   Klimyuk, Victor ^c   Hiatt, Andrew ^a   Pauly, Michael ^a   Zeitlin, Larry ^a  

^a Mapp Biopharmaceutical Inc   (United States)

^b Kentucky BioProcessing   (United States)

^c Biozentrum Halle   (Germany)

Author keywords

Antibody; Gemini; Glycan Modification; Industrialization; magnICON; Manufacturing; Nicotiana; Products; Transient Expression

Indexed keywords

ANTIFUNGAL AGENT; ANTIVIRUS AGENT; CANCER VACCINE; EBOLA VACCINE; HU E16; IMMUNOGLOBULIN; MICROBICIDE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2G8; MONOCLONAL ANTIBODY GD12; PALIVIZUMAB; PROTECTIVE AGENT; RABIES IMMUNOGLOBULIN; RICIN ANTIBODY; TRASTUZUMAB; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ANTIBODY TITER; ANTIGEN ANTIBODY COMPLEX; ARTICLE; ASPERGILLOSIS; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANDIDIASIS; COST BENEFIT ANALYSIS; CRYPTOCOCCOSIS; DOSE RESPONSE; DRUG COST; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; HUMAN; IMMUNOGENICITY; IMMUNOPROPHYLAXIS; INDUSTRIALIZATION; INFECTION PREVENTION; INTOXICATION; NICOTIANA BENTHAMIANA; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PLANT VIRUS; PRIORITY JOURNAL; REPRODUCTIVE HEALTH; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RICIN INTOXICATION; SCALE UP; SEXUAL HEALTH; SINGLE DRUG DOSE; VIRUS TITRATION; WEST NILE FEVER;

ANIMALS; ANTIBODIES, MONOCLONAL; EBOLA VACCINES; HUMANS; IMMUNOGLOBULIN IDIOTYPES; PLANT VIRUSES;

EID: 84892944316     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/82-2012-240     Document Type: Article

References (60)

1. BARDA Strategic plan 2011-2016
2. Bendandi M. (2006). Clinical benefit of idiotype vaccines: Too many trials for a clever demonstration. Rev Recent Clin Trials 1:67-74
3. Bendandi M. (2008). Aiming at a curative strategy for follicular lymphoma. CA Cancer J Clin 58:305-317
4. Bendandi M. (2009). Idiotype vaccines for lymphoma: Prof-of-principles and clinical trial failures. Nat Rev Cancer 9:675-681
5. Bendandi M, Marillonnet S, Kandzia R, et al. (2010) Rapid, high-yield production in plants of individualized idiotype vaccines for non-Hodgkin's lymphoma. Ann Oncol 21(12):2420-2427
6. Bendandi M, Becerra C, et al. (2011a) Idiotypic vaccination of patients with relapsed follicular lymphoma using a novel vaccine formulation including a tobacco plant-produced tumor specific idiotype. Blood (ASH annual meeting abstracts) 118:1649
7. Bendandi, et al. (2011b) Single agent bendamustine is an effective pre-vaccine treatment for patients with relapsed follicular lymphoma undergoing idiotypic vaccination blood (ASH annual meeting abstracts), 118: 2691
8. CAMI. (2011). Multipurpose prevention technologies for reproductive health. Report of a symposium, Washington, DC
9. Capodicasa C, Chiani P, Bromuro C, et al. (2011) Plant production of anti-glucan antibodies for immunotherapy of fungal infections in humans. Plant Biotech J 9:776-787
10. Castilho A, Strasser R, Stadlmann J, et al. (2010) In planta protein sialylation through overexpression of the respective mammalian pathway. J Biol Chem 285:15923-15930
11. Castilho A, Bohorova N, Grass J, Bohorov O, Zeitlin L, Whaley K, Altmann F, Steinkellner H. (2011). Rapid high yield production of different glycoforms of ebola virus monoclonal antibody. PLoS One 6:e26040
12. Chargelegue D, Drake PMW, Obregon P, et al. (2005) Highly immunogenic and protective recombinant vaccine candidate expressed in transgenic plant. Infect Immun 73:5915-5922
13. Cone RA, Whaley KJ. (1994). Monoclonal antibodies for reproductive health: Preventing sexual transmission of disease and pregnancy with topically applied antibodies. Am J Reprod Immunol 32:114-131
14. De Muynck B, Navarre C, Boutry M. (2010). Production of antibodies in plants: Status after twenty years. Plant Biotech J 8:529-563
15. Falsey AR, Walsh EE. (2000). Respiratory syncytial virus infection in adults. Clin Microbiol Rev 13:371-384
16. FDA. (2004). Challenge and opportunity on the critical path to new medical products, food and drug administration
17. Giritch A, Marillonnet S, Engler C, et al. (2006) Rapid high-yield expression of full-size IgG antibodies in plants coinfected with noncompeting viral vectors. PNAS 103:14701-14706
18. Gomord V, Fitchette AC, Menu Bouaouiche L, et al. (2010) Plant-specific glycosylation patterns in the context of therapeutic protein production. Plant Biotech J 8:564-587
19. Han LL, Alexander JP, Anderson LJ. (1999). Respiratory syncytial virus pneumonia among the elderly: An assessment of disease burden. J Infect Dis 179:25-30
20. Huang Z, Phoolcharoen W, Lai H, et al. (2010) High-level rapid production of full-size monoclonal antibodies in plants by a single-vector DNA replicon system. Biotechnol Bioeng 106:9-17
21. Hudis CA. (2007). Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 357:39-51
22. Hudziak RM, et al. (1989) p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 3:1165-1172
23. Joffe S, Ray GT, Escobar GJ, et al. (1999) Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatr 104:419-427
24. Kelley B. (2007). Very large scale monoclonal antibody purification: The case for conventional unit operations. Biotechnol Prog 23:995-1008
25. Klimyuk V, et al. (2012) Production of recombinant antigens and antibodies in nicotiana benthamiana using magnifection technology: GMP-compliant facilities for Small-And Large-Scale Manufacturing (THIS BOOK
26. Komarova TS, Kosorukov SV, et al. (2011) Plant-made trastuzumab (herceptin) inhibits HER2/Neu+ cell proliferation and retards tumor growth. PLoS One 6:e17541
27. Lai H, Engle M, Fuchs A, et al. (2010) Monoclonal antibody produced in plants efficiently treats west nile virus infection in mice. PNAS 107:2419-2424
28. Lai H, He J, Engle M, et al. (2012) Robust production of virus-like particles and monoclonal antibodies with geminiviral replicon vectors in lettuce. Plant Biotech J 10:95-104
29. Lopez-Diaz CA, Inoges S. (2009). Future of idiotypic vaccination for B-cell lymphoma. Expert Rev Vaccines 8:43-50
30. McCormick AA, Reinl SJ, et al. (2003) Individualized human scFv vaccines produced in plants: Humoral anti-idiotype responses in vaccinated mice confirm relevance to the tumor Ig. J Immunol Methods 278:95-104
31. McCormick AA, Reddy S, et al. (2008) Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: Safety and immunogenicity in a phase I clinical study. PNAS 105:10131-10136
32. Morris G, et al. (2010) A prospective randomized double blind placebo-controlled phase 1 pharmacokinetic and safety study of a vaginal microbicide gel containing three potent broadly neutralizing monoclonal antibodies (2F5, 2G12, 4E10) (MabGel). Microbicides (Abstract LB1
33. Neal LM, et al. (2010) A monoclonal immunoglobulin G antibody directed against an immunodominant linear epitope on the ricin A chain confers systemic and mucosal immunity to ricin. Infect Immun 78:552-61
34. Niwa R, et al. (2004) Defucosylated chimeric anti-CC chemokine receptor 4 IgGl with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res 64:2127-2133
35. O'Hara JM, Whaley KJ, Pauly M. (2012). Plant-based expression of a partially humanized neutralizing monoclonal IgG directed against an immunodominant epitope on the ricin toxin A subunit. Vaccine 30:1239-1243
36. O'Hara JM, Neal LM, McCarthy EA, et al. (2010) Folding domains within the ricin toxin A subunit as targets of protective antibodies. Vaccine 28:7035-7046
37. Olsnes S. (2004). The history of ricin, abrin and related toxins. Toxicon 44:361-370
38. Phoolcharoen W, Bhoo SH, Lai H, Ma J, Arntzen CJ, Chen Q, Mason HS (2011a) Expression of an immunogenic ebola immune complex in nicotiana benthamiana. Plant Biotech J 9:807-816
39. Phoolcharoen W, Dye JM, Kilbourne J, Piensook K, Pratt WD, Arntzen CJ, Chen Q, Mason HS, Herbst-Kralovetz MM (2011b) A nonreplicating subunit vaccine protects mice against lethal Ebola virus challenge. PNAS 108:20695-20700
40. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672
41. Pogue GP, Vojdani F, Palmer KE, et al. (2010) Production of pharmaceutical-grade recombinant aprotinin and a monoclonal antibody product using plant-based transient expression systems. Plant Biotech J 8:638-654
42. Roeckl-Wiedmann I, Liese JG, Grill E, et al. (2003) Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany. Eur J Pediatr 162:237-244
43. Sainsbury F, Lomonossoff GP. (2008). Extremely high-level and rapid protein production in plants without the use of viral replication. Plant Physiol 148:1212-1218
44. Sainsbury F, Sack M, Stadlmann J, et al. (2010) Rapid transient production in plants by replicating and non-replicating vectors yields high quality functional anti-HIV antibody. PLoS One 5:1-10
45. Schahs M, Strasser R, Stadlmann J, et al. (2007) Production of a monoclonal antibody in plants with a humanized N-glycosylation pattern. Plant Biotech J 5:657-663
46. Shields RL, et al. (2002) Lack of fucose on human IgGl N-linked oligosaccharide improves binding to human FcyRIII and antibody-dependent cellular toxicity. J Biol Chem 277:26733-26740
47. Shinkawa T, et al. (2003) The absence of fucose but not the presence of galactose or bisecting N-Acetylglucosamine of human IgGl complex-Type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 278:3466-3473
48. Slamon DJ, Leyland-Jones B, Shak S, et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792
49. Smith I, Procter M, Gelber RD, et al. (2007) Two year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomized controlled trial. Lancet 369:29-36
50. Stirpe F. (2004). Ribosome-inactivating proteins. Toxicon 15:371-383
51. Strasser R, Stadlmann J, Schahs M, et al. (2008) Generation of glyco-engineered nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure. Plant Biotech J 6:392-402
52. Strasser R, Castilho A, Stadlmann J, et al. (2009) Improved virus neutralization by plant-produced anti-HIV antibodies with a homogeneous beta1,4-galactosylated N-glycan profile. J Biol Chem 284:20479-20485
53. Vezina L-P, Faye L, Lerouge P, et al. (2009) Transient co-expression for fast and high-yield production of antibodies with human-like N-glycans in plants. Plant Biotech J 7:442-455
54. Vogel AM, McKinlay MJ, Ashton T, et al. (2002) Cost-effectiveness of palivizumab in New Zealand. J Paediatr Child Health 38:352-357
55. Werner S, Marillonnet S, Hause G, et al. (2006) Immunoabsorbent nanoparticles based on a tobamorvirus displaying protein A. PNAS 103:17678-17717
56. Whaley KJ, Hiatt A, Zeitlin A. (2011). Emerging antibody products and nicotiana manufacturing. Hum Vaccines 7:349-356
57. Wilson JA, Hevey M, Bakken R, et al. (2000) Epitopes involved in antibody-mediated protection from ebola virus. Science 287:1664-1666
58. Yermakova A, Mantis NJ. (2011). Protective immunity to ricin toxin conferred by antibodies against the toxin's binding subunit (RTB). Vaccine 29:7925-7935
59. Zeitlin L, Pettitt J, Scully C, et al. (2011) Enhanced potency of a fucose-free monoclonal antibody being developed as an ebola virus immunoprotectant. PNAS 108:20690-20694
60. Zeitlin L, et al. (2012) Prophylactic and therapeutic testing of nicotiana-derived anti-RSV human monoclonal antibodies in the cotton rat model. (Submitted